CN209361439U - It can be used for the photosensitizer bracket of photodynamic therapy treatment cholangiocarcinoma - Google Patents
It can be used for the photosensitizer bracket of photodynamic therapy treatment cholangiocarcinoma Download PDFInfo
- Publication number
- CN209361439U CN209361439U CN201821366468.2U CN201821366468U CN209361439U CN 209361439 U CN209361439 U CN 209361439U CN 201821366468 U CN201821366468 U CN 201821366468U CN 209361439 U CN209361439 U CN 209361439U
- Authority
- CN
- China
- Prior art keywords
- photosensitizer
- bracket
- cholangiocarcinoma
- layer
- photodynamic therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 50
- 208000006990 cholangiocarcinoma Diseases 0.000 title claims abstract description 43
- 238000002428 photodynamic therapy Methods 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 229920000642 polymer Polymers 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims description 10
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims description 10
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 10
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 claims description 9
- 229960002197 temoporfin Drugs 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 18
- 230000003211 malignant effect Effects 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 8
- 208000037803 restenosis Diseases 0.000 abstract description 8
- 238000007910 systemic administration Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 13
- 238000000576 coating method Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 8
- 210000003445 biliary tract Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010020718 hyperplasia Diseases 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 229920001610 polycaprolactone Polymers 0.000 description 6
- 239000004632 polycaprolactone Substances 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 239000004621 biodegradable polymer Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 239000004626 polylactic acid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 206010056375 Bile duct obstruction Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008635 Cholestasis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001523 electrospinning Methods 0.000 description 2
- 238000010041 electrostatic spinning Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The utility model relates to a kind of photosensitizer brackets that can be used for photodynamic therapy treatment cholangiocarcinoma, and the photosensitizer bracket includes rack body；The rack body is equipped with bracket overlay film internal layer；The bracket overlay film internal layer is equipped with drug-loaded layer；The drug-loaded layer includes photosensitizer layer and high polymer layer.Its advantage is shown: having by bracket prevents narrow effect, additionally by the photodynamic therapy of part, cholangiocarcinoma is treated, reduces the side effect of systemic administration bring, cholangiocarcinoma malignant proliferation bring restenosis is prevented simultaneously, the effective life quality for improving patient.
Description
Technical field
The utility model relates to the field of medical instrument technology, specifically, being that one kind can be used for photodynamic therapy treatment gallbladder
The photosensitizer bracket of pipe cancer.
Background technique
Cholangiocarcinoma is initiated by the liver malignancy of epithelium, and early stage is generally asymptomatic, when symptom occur and obtaining diagnosis and treatment
Patient is typically in progressive stage.The treatment of cholangiocarcinoma includes operation, chemicotherapy, optical dynamic therapy.Optical dynamic therapy it is external
Method through being conventional therapy cholangiocarcinoma.The side effect of photodynamic therapy is low, significant effect, can improve life in patients,
Extend patient survival, and generally resisted without treatment, is used in combination also with other therapies without taboo.Implementing the treatment of light power at present
When method, mainly by the approach of intravenously administrable, gathered using targeting of the photosensitizer for tumour, then treated.Vein
The method of administration is mainly the long retention effect of Thief zone for passing through tumour, and targeting is unsatisfactory and expensive.
Temoporfin is a kind of two generation photosensitizers, and excitation wavelength 652nm penetrates tumor tissues depth compared with generation photosensitizer
It is deep.Listing treatment head and neck neoplasm is ratified by European Union at present.This product is mainly distributed on vascular space and is swollen in tumor tissues
In oncocyte, chief destructive be tumor tissues vascular wall and direct killing tumour cell.This product is main in tumour cell
Concentrate on cytoplasm rather than in nucleus.There is clinical research discovery, the photodynamic therapy that Temoporfin mediates can be effectively improved
The life quality of cholangiocarcinoma patients extends the life span of patient.
By biodegradable polymer disclosed in the prior art for example polycaprolactone, polylactic acid, poly- hexanol acid and they
Copolymer, poly- dioxane, collagen, phosphocholine, chitosan, hyaluronic acid and hydrogel, gelatin and its derivative
Deng, have good histocompatbility, degraded in the environment of body fluid by ester linkage hydrolyzing, intermediate product lactic acid be in vivo just
The product of normal glycometabolism, final metabolite are CO2And H2O easily from internal discharge without assembling in vitals, therefore has
There is excellent biodegradable absorbability.Above-mentioned material is nontoxic, nonirritant, non-immunogenicity and biocompatibility are good,
It can be used safely in vivo, to be used as the ideal material of Slow/Controlled Release Drug.
Chinese patent literature CN97231023.1, the applying date 19971231, patent name are as follows: biliary tract portal area tissue compatible
Property reinforced Y shape inner support, discloses a kind of for treating the novel inner support of the disease of biliary tract such as cholangiocarcinoma.The inner support is in sky
Heart Y-shaped pipeline structure, is made of silica gel internal layer and dacron outer layer, is bonded between ectonexine using special process, internal layer light
It is sliding, be conducive to bile and flow through, outer layer is coarse, is conducive to suture., patient simple with structure it is painful it is small, do not block, be not easy to be formed
The advantages that calculus, can be widely used for treatment disease of biliary tract.But cholangiocarcinoma, hair are treated using photosensitizer carried stent about a kind of
That waves bracket prevents narrow effect, additionally by the photodynamic therapy of part, treats to cholangiocarcinoma.Reduce systemic administration band
The side effect come, while cholangiocarcinoma malignant proliferation bring restenosis is prevented, the technology of the effective life quality for improving patient
Scheme is not disclosed then accordingly.
In conclusion needing one kind to have by bracket prevents narrow effect, it is right additionally by the photodynamic therapy of part
Cholangiocarcinoma is treated, and reduces the side effect of systemic administration bring, while preventing cholangiocarcinoma malignant proliferation bring restenosis, has
The photosensitizer bracket of the life quality of the raising patient of effect, and yet there are no report about this photosensitizer bracket.
Summary of the invention
The purpose of this utility model is that aiming at the shortcomings in the prior art, providing a kind of bracket that plays prevents narrow work
With, additionally by the photodynamic therapy of part, cholangiocarcinoma is treated, reduces the side effect of systemic administration bring, it is anti-simultaneously
Only cholangiocarcinoma malignant proliferation bring restenosis, the photosensitizer bracket of the effective life quality for improving patient.
A further object of the utility model is: providing a kind of photosensitizer bracket that can be used for photodynamic therapy treatment cholangiocarcinoma
Preparation method.
To achieve the above object, the technical scheme adopted by the utility model is that:
A kind of photosensitizer bracket can be used for photodynamic therapy treatment cholangiocarcinoma, which is characterized in that the photosensitizer branch
Frame includes rack body；The rack body is equipped with bracket overlay film internal layer；The bracket overlay film internal layer, which is equipped with, carries medicine
Layer；The drug-loaded layer includes photosensitizer layer and high polymer layer.
As a kind of perferred technical scheme, the rack body is Nitinol precoated metal bracket.
As a kind of perferred technical scheme, the photosensitizer layer uses material to be made for Temoporfin.
As a kind of perferred technical scheme, the material of the high polymer layer uses selected from polycaprolactone, gathers
Lactic acid, poly- hexanol acid and their copolymer, poly- dioxane, collagen, phosphocholine, chitosan, hyaluronic acid and
At least one of hydrogel, gelatin and its derivative.
To realize above-mentioned second purpose, the technical scheme adopted by the utility model is that:
A kind of preparation method for the photosensitizer bracket can be used for photodynamic therapy treatment cholangiocarcinoma, the preparation method include
Following steps:
It step S1, will be spare after Nitinol overlay film frame 60Co irradiation sterilization；
Step S2, proportionally, biodegradable polymer will be dissolved into dichloromethane or chloroform or tetrahydro furan
Mutter or acetone or carbon tetrachloride or dimethylformamide in, solution is made, photosensitizer is dispersed in the biodegradable
In polymer solution, by mixing electrospinning process, the rack surface of the S1 preparation is set, cholangiocarcinoma photosensitizer is made
Coating stent of medicine；
Step S3, cholangiocarcinoma photosensitizer drug coating bracket obtained in above-mentioned steps S2 is placed in a vacuum drying oven,
31-45 DEG C of drying, and with oxirane disinfection post package.
As a kind of perferred technical scheme, bracket used is Nitinol overlay film frame.
As a kind of perferred technical scheme, the biodegradable polymer is polycaprolactone, polylactic acid, poly- hexanol
Acid, polylactide-polyglycolic acid copolymer, polycaprolactone-copolymer of poly lactic acid, poly- dioxane, collagen, phosphocholine,
Gelatin or chitosan and its derivative are at least one.
The utility model advantage is:
(1) the photosensitizer drug coating bracket of this treatment cholangiocarcinoma, using Nitinol overlay film frame as raw material, radial support
Better performances can prevent cholangiocarcinoma malignant proliferation to be closed, and keep biliary tract unobstructed；
(2) this bracket coating pharmaceutical carrier is biodegradable polymer, and biocompatibility is preferable, acts in vivo few
Inflammation；
(3) it can be repeated several times row optical dynamic therapy bile duct using the photosensitizer of the polymer coating slow release containing drug
Cancer, anti-cholangiocarcinoma cell malignant proliferation and narrow avoid aggravating obstruction of bile duct after restenosis occurs, are effectively improved survival of patients
Quality.
(4) coating stent of medicine of the treatment cholangiocarcinoma of the utility model can pass through light partially into cholangiocarcinoma
Motivation therapy effectively prevent the histio-irritative hyperplasia of support portions or the significant hyperplasia of tumor tissues, had both improved curative effect and has decreased
The systemic side effects of photosensitizer intravenously administrable；Which reduce the hyperplasia pathological reaction of local anomaly, avoid after restenosis occurs
Aggravate obstruction.
Detailed description of the invention
Attached drawing 1 is that a kind of structure of photosensitizer bracket that can be used for photodynamic therapy treatment cholangiocarcinoma of the utility model is shown
It is intended to.
Specific embodiment
It elaborates with reference to the accompanying drawing to specific embodiment provided by the utility model.
Appended drawing reference involved in attached drawing and component part are as follows:
1. 11. bracket overlay film internal layer of rack body
12. 13. photosensitizer layer of drug-loaded layer
14. high polymer layer
The structure of 1 photosensitizer bracket of embodiment
Fig. 1 is please referred to, Fig. 1 is a kind of photosensitizer bracket that can be used for photodynamic therapy treatment cholangiocarcinoma of the utility model
Structural schematic diagram.A kind of photosensitizer bracket can be used for photodynamic therapy treatment cholangiocarcinoma, the photosensitizer bracket include
Rack body 1；The rack body 1 is equipped with bracket overlay film internal layer 11；The bracket overlay film internal layer 11, which is equipped with, carries medicine
Layer 12；The drug-loaded layer 12 includes photosensitizer layer 13 and high polymer layer 14.
The embodiment it should be understood that
The photosensitizer bracket of the utility model is covered on tumor surface, can be targeted by way of local sustained release into tumour
In tissue, the targeting of photodynamic therapy is not only can be improved in this, while can effectively reduce drug dose, this is also further reduced
Side effects of pharmaceutical drugs, and reduce financial burden.
The rack body 1 is Nitinol precoated metal bracket.With good tension force effect, support effect is good.
The photosensitizer layer 13 uses material to be made for Temoporfin, is treated by the light power that Temoporfin mediates
Method can be effectively improved the life quality of cholangiocarcinoma patients, extend the life span of patient.
The material of the high polymer layer 14 use selected from polycaprolactone, polylactic acid, poly- hexanol acid and they
Copolymer, poly- dioxane, collagen, phosphocholine, chitosan, hyaluronic acid and hydrogel, gelatin and its derivative
Etc. at least one.With good histocompatbility, degraded in the environment of body fluid by ester linkage hydrolyzing, intermediate product lactic acid
It is the product of internal normal sugar metabolism, final metabolite is CO2And H2O, easily from internal discharge without poly- in vitals
Collection, therefore there is excellent biodegradable absorbability.Above-mentioned material is nontoxic, nonirritant, non-immunogenicity and biofacies
Capacitive is good, can be used safely in vivo, to be used as the ideal material of Slow/Controlled Release Drug.
The preparation method (one) of 2 photosensitizer bracket of embodiment
(1) Nitinol peritonaeum bracket is spare after 60Co irradiation sterilization；
(2) in 20mg: 1ml ratio, polycaprolactone is dissolved into acetone, solution is made, by Temoporfin and high score
Sub- material is proportionally dispersed in the polycaprolactone solution, and by spray treatment, setting is prepared in the step (1)
Rack surface, that is, anti-cholangiocarcinoma photosensitizer drug coating bracket is made；
(3) it is placed in a vacuum drying oven after the medication coat preparation of biliary tract prosthesis, 45 DEG C of dryings, and uses ethylene oxide
Sterilize post package.
The preparation method (two) of 3 photosensitizer bracket of embodiment
(1) Nitinol peritonaeum bracket is spare after 60Co irradiation sterilization
(2) according to the ratio of 80mg:1ml, Poly L-lactide-caprolactone is dissolved in hexafluoroisopropanol, is made 8%
Electrostatic spinning solution.
(3) Temoporfin of 500mg is added in the above solution, is uniformly mixed using magnetic stirring apparatus.
(4) using the method for mixing electrostatic spinning by the solution cospinning of above-mentioned (3) in the surface of Nitinol overlay film frame,
Drug-loading fibre film is made.It is placed in a vacuum drying oven after the medication coat preparation of biliary tract prosthesis, 45 DEG C of dryings, and uses epoxy
Ethane sterilizes post package.
The preparation method (three) of 4 photosensitizer bracket of embodiment
Firstly, nick-eltitanium alloy stent is respectively placed in 60Co irradiation sterilization；Then, in 50mg: 1ml ratio, shell is gathered
Sugar is dissolved into carbon tetrachloride, and solution is made, and the Temoporfin that quality is 500mg is dispersed in the chitosan solution
In, then by electrospinning process, be placed in the rack surface, anti-cholangiocarcinoma photosensitizer drug coating bracket is made；Finally,
Above-mentioned anti-cholangiocarcinoma photosensitizer drug coating bracket is placed in a vacuum drying oven, 45 DEG C of dryings, and with after oxirane disinfection
Encapsulation.
A kind of photosensitizer bracket can be used for photodynamic therapy treatment cholangiocarcinoma of the utility model is imitated with following technology
Fruit:
(1) the photosensitizer drug coating bracket of this treatment cholangiocarcinoma, using Nitinol overlay film frame as raw material, radial support
Better performances can prevent cholangiocarcinoma malignant proliferation to be closed, and keep biliary tract unobstructed；
(2) this bracket coating pharmaceutical carrier is biodegradable polymer, and biocompatibility is preferable, acts in vivo few
Inflammation；
(3) it can be repeated several times row optical dynamic therapy bile duct using the photosensitizer of the polymer coating slow release containing drug
Cancer, anti-cholangiocarcinoma cell malignant proliferation and narrow avoid aggravating obstruction of bile duct after restenosis occurs, are effectively improved survival of patients
Quality.
(4) coating stent of medicine of the treatment cholangiocarcinoma of the utility model can pass through light partially into cholangiocarcinoma
Motivation therapy effectively prevent the histio-irritative hyperplasia of support portions or the significant hyperplasia of tumor tissues, had both improved curative effect and has decreased
The systemic side effects of photosensitizer intravenously administrable；Which reduce the hyperplasia pathological reaction of local anomaly, avoid after restenosis occurs
Aggravate obstruction.
The above is only the preferred embodiment of the utility model, it is noted that for the common skill of the art
Art personnel can also make several improvement and supplement under the premise of not departing from the utility model method, these are improved and supplement
Also it should be regarded as the protection scope of the utility model.
Claims (3)
1. a kind of photosensitizer bracket that can be used for photodynamic therapy treatment cholangiocarcinoma, which is characterized in that the photosensitizer bracket
Including rack body；The rack body is equipped with bracket overlay film internal layer；The bracket overlay film internal layer is equipped with drug-loaded layer；
The drug-loaded layer includes photosensitizer layer and high polymer layer.
2. the photosensitizer bracket according to claim 1 that can be used for photodynamic therapy treatment cholangiocarcinoma, which is characterized in that institute
The rack body stated is Nitinol precoated metal bracket.
3. the photosensitizer bracket according to claim 1 that can be used for photodynamic therapy treatment cholangiocarcinoma, which is characterized in that institute
The photosensitizer layer stated uses material to be made for Temoporfin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201821366468.2U CN209361439U (en) | 2018-08-23 | 2018-08-23 | It can be used for the photosensitizer bracket of photodynamic therapy treatment cholangiocarcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201821366468.2U CN209361439U (en) | 2018-08-23 | 2018-08-23 | It can be used for the photosensitizer bracket of photodynamic therapy treatment cholangiocarcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN209361439U true CN209361439U (en) | 2019-09-10 |
Family
ID=67823229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201821366468.2U Expired - Fee Related CN209361439U (en) | 2018-08-23 | 2018-08-23 | It can be used for the photosensitizer bracket of photodynamic therapy treatment cholangiocarcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN209361439U (en) |
-
2018
- 2018-08-23 CN CN201821366468.2U patent/CN209361439U/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210338570A1 (en) | Radiation sensitizer or anti-cancer chemotherapy sensitizer | |
| Won et al. | 3D printing of drug-loaded multi-shell rods for local delivery of bevacizumab and dexamethasone: A synergetic therapy for retinal vascular diseases | |
| US6344050B1 (en) | Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue | |
| Yang et al. | Paying attention to tumor blood vessels: cancer phototherapy assisted with nano delivery strategies | |
| Chang et al. | Hypocrellin B and paclitaxel-encapsulated hyaluronic acid–ceramide nanoparticles for targeted photodynamic therapy in lung cancer | |
| CN106727314A (en) | A kind of preparation of sensitising agent based on hyaluronic acid/antineoplastic self-assembled nanometer delivery system and sign | |
| Ahn et al. | Photodynamic therapy for breast cancer in a BALB/c mouse model | |
| KR20140110757A (en) | Use of Photosensitizer In Preparation of Virus-Inactivating Medicaments For Treating Diseases | |
| CN107812008A (en) | A kind of preparation method of near-infrared fluorescence imaging small molecule anti-cancer Nano medication | |
| CN107875140A (en) | A kind of double targeted drug delivery systems and its application in oncotherapy preparation is prepared | |
| Sharma et al. | Mechanisms of photodynamic therapy | |
| CN106729774A (en) | Load tanshinone inversion of phases nanometer acoustic contrast agent of enoxolone modification and preparation method thereof | |
| Ren et al. | Macrophage-mediated multi-mode drug release system for photothermal combined with anti-inflammatory therapy against postoperative recurrence of triple negative breast cancer | |
| CN104888219B (en) | A kind of tumour phototherapy reagent coated based on cell membrane and its preparation method and application | |
| CN209361439U (en) | It can be used for the photosensitizer bracket of photodynamic therapy treatment cholangiocarcinoma | |
| Wang et al. | Efficient tumor treatment by triphenylphosphine conjugated nanocellulose composite hydrogels for enhanced mitochondria targeting | |
| CN108888808A (en) | A kind of photosensitizer bracket can be used for photodynamic therapy treatment cholangiocarcinoma | |
| TWI674110B (en) | Drug carrier and manufacturing method thereof | |
| Song et al. | Combination of Molecule-Targeted Therapy and Photodynamic Therapy Using Nanoformulated Verteporfin for Effective Uveal Melanoma Treatment | |
| CN103110568A (en) | Nanometer drug delivery system carrying tanshinone IIA | |
| CN105582539B (en) | It is a kind of for glioma cell and its rely on blood vessel drug delivery system | |
| CN106619569A (en) | Tumor-targeting nanoparticles co-loading chemotherapy drug and nucleic acid and preparation method thereof | |
| CN106727444A (en) | A kind of novel medicinal film | |
| CN100534428C (en) | Application of haematopophyrin in treating ophthalmic disease | |
| Naik et al. | Biomaterials in Drug Delivery Systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190910 |